Combination Ezetimibe/Rosuvastatin Beats Rosuvastatin Alone in Hypercholesterolemia

Share this content:
The combination of ezetimibe and rosuvastatin appeared to be more effective than rosuvastatin alone.
The combination of ezetimibe and rosuvastatin appeared to be more effective than rosuvastatin alone.

(HealthDay News) — For patients with primary hypercholesterolemia, fixed-dose combination of ezetimibe plus rosuvastatin is more effective than rosuvastatin alone, according to a study published in Cardiovascular Therapeutics.

Kyung-Jin Kim, from Seoul National University in South Korea, and colleagues compared the effects of fixed-dose combinations of ezetimibe plus rosuvastatin to rosuvastatin alone in patients with primary hypercholesterolemia in an 8-week randomized trial. A total of 407 patients with primary hypercholesterolemia who required lipid-lowering treatment were randomly allocated to fixed-dose combinations with ezetimibe 10 mg daily plus rosuvastatin (5, 10, or 20 mg) or to rosuvastatin alone (5, 10, or 20 mg).

The researchers observed a significant reduction in LDL cholesterol, total cholesterol, and triglyceride levels for fixed-dose combinations of ezetimibe plus rosuvastatin vs rosuvastatin alone. Ezetimibe plus rosuvastatin provided reductions of 56% to 63% in LDL cholesterol, 37% to 43% in total cholesterol, and 19% to 24% in triglycerides, depending on the dose of rosuvastatin. 

The effect of combination treatment was stronger in patients with diabetes or metabolic syndrome vs those without diabetes or metabolic syndrome; there were no differences in the effect of rosuvastatin alone for diabetes vs non-diabetes or metabolic syndrome vs non-metabolic syndrome patients.

"Fixed-dose combinations of ezetimibe and rosuvastatin provided significantly superior efficacy to rosuvastatin alone in lowering LDL cholesterol, total cholesterol, and triglyceride levels," the researchers wrote.

Reference

  1. Kim K-J, Kim S-H, Yoon YW, et al. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia:MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc Ther. 2016. doi:10.1111/1755-5922.12213.
You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus